Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Golcadomide, Poseltinib, and Rituximab for Optimized Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma (Go-Pro-DLBCL)

NCT07269639 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT07269639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07269639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Golcadomide, Poseltinib, and Rituximab for Optimized Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma (Go-Pro-DLBCL)
Lead sponsor
Seoul National University Hospital
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
January 1, 2026
Completion date
September 1, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

large b-cell lymphoma (lbcl)